Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas

NCT04669197 is registered in ClinicalTrials.gov with HonorHealth Research Institute as lead sponsor.

NCT NCT04669197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Lead sponsor
HonorHealth Research Institute
Phase
Phase 2
Overall status
Completed
Start date
December 1, 2020
Completion date
July 31, 2025
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic adenocarcinoma, locally advanced pancreatic adenocarcinoma, untreated resectable pancreatic adenocarcinoma